Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Description
N/A
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.03 - 0.16
Trade Value (12mth)
AU$11,741.00
1 week
-4.35%
1 month
0%
YTD
19.57%
1 year
12.24%
All time high
0.46
EPS 3 yr Growth
-71.90%
EBITDA Margin
N/A
Operating Cashflow
-$1m
Free Cash Flow Return
-16.40%
ROIC
-29.80%
Interest Coverage
N/A
Quick Ratio
7.00
Shares on Issue (Fully Dilluted)
190m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
17 April 25 |
Results of Meeting
×
Results of Meeting |
15 April 25 |
Quarterly Activities Report and Appendix 4C
×
Quarterly Activities Report and Appendix 4C |
09 April 25 |
Phase I Clinical Trial Dosing Update No 1
×
Phase I Clinical Trial Dosing Update No 1 |
09 April 25 |
Notice of Initial Substantial Holder - M Azzi
×
Notice of Initial Substantial Holder - M Azzi |
07 April 25 |
Significant Neuroprotection in Traumatic Brain Injury Study
×
Significant Neuroprotection in Traumatic Brain Injury Study |
31 March 25 |
First Cohort Dosed in Nyradas Phase I Clinical Trial
×
First Cohort Dosed in Nyradas Phase I Clinical Trial |
17 March 25 |
Nyrada Commences Phase I Clinical Trial Recruitment
×
Nyrada Commences Phase I Clinical Trial Recruitment |
12 March 25 |
2025 EGM Letter to Shareholders, Notice of Meeting and Proxy
×
2025 EGM Letter to Shareholders, Notice of Meeting and Proxy |
18 February 25 |
Appendix 4D and Half Year Report to 31 December 2024
×
Appendix 4D and Half Year Report to 31 December 2024 |
18 February 25 |
Nyrada Half Year Results FY2025
×
Nyrada Half Year Results FY2025 |
07 February 25 |
Nyrada to Commence Phase Ia Clinical Trial
×
Nyrada to Commence Phase Ia Clinical Trial |
23 January 25 |
Change of Director's Interest Notice - JM
×
Change of Director's Interest Notice - JM |
23 January 25 |
Quarterly Activities Report and Appendix 4C
×
Quarterly Activities Report and Appendix 4C |
22 January 25 |
Change of Director's Interest Notice - CC
×
Change of Director's Interest Notice - CC |
22 January 25 |
Change of Director's Interest Notice - RW
×
Change of Director's Interest Notice - RW |
22 January 25 |
Change of Director's Interest Notice - MF
×
Change of Director's Interest Notice - MF |
21 January 25 |
Notification of cessation of securities - NYR
×
Notification of cessation of securities - NYR |
21 January 25 |
Change of Director's Interest Notice - ID
×
Change of Director's Interest Notice - ID |
31 December 24 |
NYR-BI03 Phase Ia Clinical Trial Update 2
×
NYR-BI03 Phase Ia Clinical Trial Update 2 |
24 December 24 |
Nyrada Receives A$1.235M R&D Tax Incentive Rebate
×
Nyrada Receives A$1.235M R&D Tax Incentive Rebate |
23 December 24 |
Upcoming Expiry of Unlisted Warrants
×
Upcoming Expiry of Unlisted Warrants |
17 December 24 |
NYR-BI03 Phase Ia Clinical Trial Update - Correction
×
NYR-BI03 Phase Ia Clinical Trial Update - Correction |
16 December 24 |
NYR-BI03 Phase Ia Clinical Trial Update
×
NYR-BI03 Phase Ia Clinical Trial Update |
09 December 24 |
Application for quotation of securities - NYR
×
Application for quotation of securities - NYR |
06 December 24 |
Securities Purchase Plan Closure
×
Securities Purchase Plan Closure |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.